Articles

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis

Department of Haematology, Lille University Hospital, Lille
Department of Hematology, University Hospital Hôtel-Dieu, Nantes
Perth Blood Institute, Murdoch University, Perth
Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex
Department of Hematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris
Department of Hematology, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite
Sanofi, Cambridge, MA
Sanofi, Cambridge, MA
Sanofi R-D, Chilly-Mazarin
Sanofi R-D, Vitry-sur-Seine
Department of Hematology, University of California at San Francisco, San Francisco, CA
Haematologica Early view Aug 17, 2023 https://doi.org/10.3324/haematol.2023.283073